Convergence in the Epidemiology and Pathogenesis of COPD and Pneumonia

References

• Marshall B, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 323(8390):1311–1315.
   Google Scholar
• Fock KM, Graham DY, Malfertheiner P. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol 2013; 10(8):495–500.
   Google Scholar
• Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, Committee GS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163(5):1256–1276.
   PubMedGoogle Scholar
• Petty TL. The history of COPD. Int J Chron Obstruct Pulmon Dis 2006; 1(1):3–14.
   PubMedGoogle Scholar
• World Health Organization. The top 10 causes of deaths. WHO [Internet]. 2014 [cited November 2015]. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/
   Google Scholar
• World Health Organization. Burden of COPD. WHO [Internet].[cited November 2015]. Available from:http://www.who.int/respiratory/copd/burden/en/
   Google Scholar
• Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990.2020: Global Burden of Disease Study. Lancet 1997; 349(9064):1498–1504.
   Google Scholar
• O'Toole RF, Shukla SD, Walters EH. TB meets COPD: an emerging global co-morbidity in human lung disease. Tuberculosis (Edinb) 2015; 95(6):659–663.
   PubMed Web of Science ®Google Scholar
• Singh YD. Pathophysiology of community acquired pneumonia. J Assoc Phys India 2012; 60 Suppl:7–9.
   PubMedGoogle Scholar
• Alcon A, Fabregas N, Torres A. Pathophysiology of pneumonia. Clin Chest Med 2005; 26(1):39–46.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pneumonia. WHO [Internet]. 2015 [cited November 2015]. Available from: http://www.who.int/mediacentre/factsheets/fs331/en/
   Google Scholar
• Carbon C. Pneumonia in the elderly. Int J Antimicrob Agents 1993; 3 Suppl 1:S119–S126.
   Google Scholar
• Stupka JE, Mortensen EM, Anzueto A, Restrepo MI. Community-acquired pneumonia in elderly patients. Aging Health 2009; 5(6):763–774.
   PubMedGoogle Scholar
• Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5(4):549–555.
   PubMedGoogle Scholar
• Hayden LP, Hobbs BD, Cohen RT, Wise RA, Checkley W, Crapo JD, et al. Childhood pneumonia increases risk for chronic obstructive pulmonary disease: the COPDGene study. Respir Res 2015; 16(1):115.
   PubMed Web of Science ®Google Scholar
• Hayden L. On medicine: Does COPD begin in childhood? Biomed Central [Internet]. 2015 [cited November 2015]. Available from: http://blogs.biomedcentral.com/on-medicine/2015/11/18/copd-begin-childhood/
   Google Scholar
• Sibila O, Soto-Gomez N, Restrepo MI. The risk and outcomes of pneumonia in patients on inhaled corticosteroids. Pulm Pharmacol Ther 2015; 32:130–136.
   PubMed Web of Science ®Google Scholar
• Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61(11):935–939.
   PubMed Web of Science ®Google Scholar
• Lundback B, Lindberg A, Lindstrom M, Ronmark E, Jonsson AC, Jonsson E, et al. Not 15 but 50% of smokers develop COPD?—Report from the obstructive lung disease in Northern Sweden studies. Respir Med 2003; 97(2):115–122.
   PubMed Web of Science ®Google Scholar
• Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. The Lancet 2007; 370(9589):765–773.
   PubMed Web of Science ®Google Scholar
• Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 2013; 68(11):1057–1065.
   PubMed Web of Science ®Google Scholar
• Almirall J, Serra-Prat M, Bolíbar I, Palomera E, Roig J, Hospital I, et al. Passive smoking at home is a risk factor for community-acquired pneumonia in older adults: a population-based case–control study. BMJ Open 2014; 4(6):e005133.
   PubMed Web of Science ®Google Scholar
• Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, et al. Cigarette smoking and invasive pneumococcal disease. Active bacterial core surveillance team. N Engl J Med 2000; 342(10):681–689.
   PubMed Web of Science ®Google Scholar
• Fullerton DG, Bruce N, Gordon SB. Indoor air pollution from biomass fuel smoke is a major health concern in the developing world. Trans R Soc Trop Med Hyg 2008; 102(9):843–851.
   PubMed Web of Science ®Google Scholar
• Taylor ET, Nakai S. Prevalence of acute respiratory infections in women and children in Western Sierra Leone due to smoke from wood and charcoal stoves. Int J Environ Res Public Health 2012; 9(6):2252–2265.
   PubMed Web of Science ®Google Scholar
• Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182(5):693–718.
   PubMed Web of Science ®Google Scholar
• Liu R, Zhang X, Pu Y, Yin L, Li Y, Zhang X, et al. Small-sized titanium dioxide nanoparticles mediate immune toxicity in rat pulmonary alveolar macrophages. J Nanosci Nanotechnol 2010; 10(8):5161–5169.
   PubMed Web of Science ®Google Scholar
• Palmer KT, Poole J, Ayres JG, Mann J, Burge PS, Coggon D. Exposure to metal fume and infectious pneumonia. Am J Epidemiol 2003; 157(3):227–233.
   PubMed Web of Science ®Google Scholar
• Prescott E, Lange P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: Results from the Copenhagen City Heart Study. Eur Respir J 1999; 13(5): 1109–1114.
   Google Scholar
• Barker DJ, Godfrey KM, Fall C, Osmond C, Winter PD, Shaheen SO. Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. BMJ 1991; 303(6804):671–675.
   PubMed Web of Science ®Google Scholar
• Loeb MB. Use of a broader determinants of health model for community-acquired pneumonia in seniors. Clin Infect Dis 2004; 38(9):1293–1297.
   PubMed Web of Science ®Google Scholar
• Thorn L, Minamisava R, Nouer S, Ribeiro L, Andrade A. Pneumonia and poverty: a prospective population-based study among children in Brazil. BMC Infect Dis 2011; 11(1):180.
   PubMed Web of Science ®Google Scholar
• Boé DM, Vandivier RW, Burnham EL, Moss M. Alcohol abuse and pulmonary disease. J Leukoc Biol 2009; 86(5):1097–1104.
   PubMed Web of Science ®Google Scholar
• Sisson JH. Alcohol and airways function in health and disease. Alcohol 2007; 41(5):293–307.
   PubMed Web of Science ®Google Scholar
• Happel KI, Nelson S. Alcohol, Immunosuppression, and the Lung. Proc Am Thorac Soc 2005; 2(5):428–432.
   PubMedGoogle Scholar
• Chou C-Y, Wang S-M, Liang C-C, Chang C-T, Liu J-H, Wang IK, et al. Risk of pneumonia among patients with chronic kidney disease in outpatient and inpatient settings: a nationwide population-based study. Medicine 2014; 93(27):e174.
   Google Scholar
• Yoshizawa T, Okada K, Furuichi S, Ishiguro T, Yoshizawa A, Akahoshi T, et al. Prevalence of chronic kidney diseases in patients with chronic obstructive pulmonary disease: assessment based on glomerular filtration rate estimated from creatinine and cystatin C levels. Int J Chron Obstruct Pulmon Dis 2015; 10:1283–1289.
   PubMed Web of Science ®Google Scholar
• Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64(12):1062–1069.
   PubMed Web of Science ®Google Scholar
• Australian Bureau of Statistics. 3303.0–Causes of Death, Australia. ABS [Internet]. 2014 [cited November 2015]. Available from: http://www.abs.gov.au/ausstats/[email protected]/Lookup/by%20Subject/3303.0∼2012∼Main%20Features∼Diseases%20of%20the%20Respiratory%20System%20(J00-J99)∼10032
   Google Scholar
• Raherison C, Girodet P-O. Epidemiology of COPD. Eur Respir Rev 2009; 18(114):213–221.
   PubMedGoogle Scholar
• Boyd AR, Orihuela CJ. Dysregulated inflammation as a risk factor for pneumonia in the elderly. Aging Dis 2011; 2(6):487–500.
   PubMed Web of Science ®Google Scholar
• Morris A, George MP, Crothers K, Huang L, Lucht L, Kessinger C, et al. HIV and chronic obstructive pulmonary disease: is it worse and why? Proc Am Thorac Soc 2011; 8(3):320–325.
   PubMedGoogle Scholar
• Sethi S. Bacterial infection and the pathogenesis of copd*. Chest 2000; 117(5_suppl_1):286S–291S.
   Google Scholar
• Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 2013; 68(11):1057–1065.
   PubMed Web of Science ®Google Scholar
• Sogaard OS, Lohse N, Gerstoft J, Kronborg G, Ostergaard L, Pedersen C, et al. Hospitalization for pneumonia among individuals with and without HIV infection, 1995–2007: a Danish population-based, nationwide cohort study. Clin Infect Dis 2008; 47(10):1345–1353.
   PubMed Web of Science ®Google Scholar
• Laheij RF, Sturkenboom MM, Hassing R, Dieleman J, Stricker BC, Jansen JJ. RIsk of community-acquired pneumonia and use of gastric acid–suppressive drugs. JAMA 2004; 292(16):1955–1960.
   PubMed Web of Science ®Google Scholar
• Ruhl CE, Sonnenberg A, Everhart JE. Hospitalization with respiratory disease following hiatal hernia and reflux esophagitis in a prospective, population-based study. Ann Epidemiol 2001; 11(7):477–483.
   PubMed Web of Science ®Google Scholar
• Aybay C, Imir T, Okur H. The effect of omeprazole on human natural killer cell activity. Gen Pharmacol 1995; 26(6):1413–1418.
   PubMedGoogle Scholar
• Scaringi L, Cornacchione P, Fettucciari K, Rosati E, Rossi R, Marconi P, et al. Activity inhibition of cytolytic lymphocytes by omeprazole. Scand J Immunol 1996; 44(3):204–214.
   PubMed Web of Science ®Google Scholar
• Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996; 39(1):54–59.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Nakayama K, Yasuda H, Yamaya M. A new strategy with proton pump inhibitors for the prevention of acute exacerbations in COPD. Ther Adv Respir Dis 2011; 5(2):91–103.
   PubMedGoogle Scholar
• Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O. Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica 2014; 99(2):392–398.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343(4):269–280.
   PubMed Web of Science ®Google Scholar
• Hayden L, Hobbs B, Cohen R, Wise R, Checkley W, Crapo J, et al. Childhood pneumonia increases risk for chronic obstructive pulmonary disease: the COPDGene study. Respir Res 2015; 16(1):115.
   PubMed Web of Science ®Google Scholar
• Hwang YI, Lee SH, Yoo JH, Jung BH, Yoo KH, Na MJ, et al. History of pneumonia is a strong risk factor for chronic obstructive pulmonary disease (COPD) exacerbation in South Korea. J Thorac Dis 2015; 7(12):2203–2213.
   PubMed Web of Science ®Google Scholar
• Shaheen SO, Barker DJ, Shiell AW, Crocker FJ, Wield GA, Holgate ST. The relationship between pneumonia in early childhood and impaired lung function in late adult life. Am J Respir Crit Care Med 1994; 149(3):616–619.
   PubMed Web of Science ®Google Scholar
• Shaheen SO, Sterne JAC, Tucker JS, Florey CdV. Birth weight, childhood lower respiratory tract infection, and adult lung function. Thorax 1998; 53(7):549–553.
   PubMed Web of Science ®Google Scholar
• Lange P, Celli B, Agustí A, Boje Jensen G, Divo M, Faner R, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 2015; 373(2):111–122.
   PubMed Web of Science ®Google Scholar
• Rubin BK, Dhand R, Ruppel GL, Branson RD, Hess DR. Respiratory care year in review 2010: Part 1. Asthma, COPD, pulmonary function testing, ventilator-associated pneumonia. Respir Care 2011; 56(4):488–502.
   PubMed Web of Science ®Google Scholar
• Svanes C, Sunyer J, Plana E, Dharmage S, Heinrich J, Jarvis D, et al. Early life origins of chronic obstructive pulmonary disease. Thorax 2010; 65(1):14–20.
   PubMed Web of Science ®Google Scholar
• Mullerova H, Chigbo C, Hagan GW, Woodhead MA, Miravitlles M, Davis KJ, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012; 106(8):1124–1133.
   PubMed Web of Science ®Google Scholar
• Lung foundation Australia. COPD-X Concise Guide for Primary Care. COPD-X [Internet]. 2014 [cited November 2015]. Available from: http://copdx.org.au/wp-content/uploads/2015/08/LFA-COPD-X-doc_V3.02_0815_WEB.pdf
   Google Scholar
• Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68(11):1029–1036.
   PubMed Web of Science ®Google Scholar
• Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009; 169(3):219–229.
   PubMed Web of Science ®Google Scholar
• Joo MJ, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 2010; 104(2):246–252.
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. The Cochrane database of systematic reviews 2012; 9:CD006829–CD.
   PubMed Web of Science ®Google Scholar
• Janson C, Larsson K, Lisspers KH, Ställberg B, Stratelis G, Goike H, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS). BMJ 2013; 346:f3306.
   PubMed Web of Science ®Google Scholar
• Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med 2012; 106(2):257–268.
   PubMed Web of Science ®Google Scholar
• Iannella H, Luna C, Waterer G. Inhaled corticosteroids and the increased risk of pneumonia: what's new? A 2015 updated review. Ther Adv Respir Dis 2016 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50μg) or salmeterol (50μg) on COPD exacerbations. Respir Med 2008; 102(8):1099–1108.
   PubMed Web of Science ®Google Scholar
• Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176(2):162–166.
   PubMed Web of Science ®Google Scholar
• Eapen MS, Shukla SD, Mahmood MQ, McAlinden-Volkovickas K, Eri RD, Walters EH, et al. Current understanding of corticosteroid therapy in chronic obstructive pulmonary disease (COPD): an overview. Int J Med Biol Front 2015; 21(1):1–29.
   Google Scholar
• Søgaard M, Madsen M, Løkke A, Hilberg O, Sørensen HT, Thomsen RW. Incidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumonia. Int J Chron Obstruct Pulmon Dis 2016; 11:455–65.
   PubMed Web of Science ®Google Scholar
• Welte T. Inhaled corticosteroids in COPD and the risk of pneumonia. Lancet 2009; 374(9691):668–670.
   PubMed Web of Science ®Google Scholar
• Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J 2012; 22:92.
   Google Scholar
• Aberdein JD, Cole J, Bewley MA, Marriott HM, Dockrell DH. Alveolar macrophages in pulmonary host defence the unrecognized role of apoptosis as a mechanism of intracellular bacterial killing. Clin Exp Immunol 2013; 174(2):193–202.
   PubMed Web of Science ®Google Scholar
• Stolberg VR, McCubbrey AL, Freeman CM, Brown JP, Crudgington SW, Taitano SH, et al. Glucocorticoid-augmented efferocytosis inhibits pulmonary pneumococcal clearance in mice by reducing alveolar macrophage bactericidal function. J Immunol 2015; 195(1):174–184.
   PubMed Web of Science ®Google Scholar
• Patterson CM, Morrison RL, D'Souza A, Teng XS, Happel KI. Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella pneumoniae in mice. Respir Res 2012; 13:40.
   PubMed Web of Science ®Google Scholar
• Delclaux C, Azoulay E. Inflammatory response to infectious pulmonary injury. Eur Respir J 2003; 22(42 suppl):10s–14s.
   Google Scholar
• Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364(9435):709–721.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008; 8(3):183–192.
   Google Scholar
• Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for Macrophage Elastase for Cigarette Smoke-Induced Emphysema in Mice. Science 1997; 277(5334):2002–2004.
   Google Scholar
• Halwani R, Al-Muhsen S, Al-Jahdali H, Hamid Q. Role of Transforming Growth Factor-β in Airway Remodeling in Asthma. Am J Respir Cell Mol Biol 2011; 44(2):127–133.
   Google Scholar
• Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153(5):1530–1535.
   Google Scholar
• Curtis JL, Freeman CM, Hogg JC. The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research. Proc Am Thorac Soc 2007; 4(7):512–521.
   PubMedGoogle Scholar
• Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163(6):1304–1309.
   PubMed Web of Science ®Google Scholar
• Chen K, Kolls JK. T cell–mediated host immune defenses in the ung. Annu Rev Immunol 2013; 31(1):605–633.
   PubMed Web of Science ®Google Scholar
• Bogaert D, de Groot R, Hermans PWM. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4(3):144–154.
   PubMed Web of Science ®Google Scholar
• Winkelstein JA, Tomasz A. Activation of the Alternative Complement Pathway by Pneumococcal Cell Wall Teichoic Acid. J Immunol 1978; 120(1):174–178.
   Google Scholar
• Mook-Kanamori BB, Geldhoff M, van der Poll T, van de Beek D. Pathogenesis and Pathophysiology of Pneumococcal Meningitis. Clin Microbiol Rev 2011; 24(3):557–591.
   Google Scholar
• Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2009; 22(2):240–273.
   PubMed Web of Science ®Google Scholar
• MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Clin Chest Med 2007; 28(3):479–513.
   PubMed Web of Science ®Google Scholar
• Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000; 13(3):470–511.
   PubMed Web of Science ®Google Scholar
• Moldoveanu B, Otmishi P, Jani P, Walker J, Sarmiento X, Guardiola J, et al. Inflammatory mechanisms in the lung. J Inflamm Res 2009; 2:1–11.
   PubMedGoogle Scholar
• Edmond K, Scott S, Korczak V, Ward C, Sanderson C, Theodoratou E, et al. Long term sequelae from childhood pneumonia; systematic review and meta-analysis. PLoS ONE 2012; 7(2):e31239.
   PubMed Web of Science ®Google Scholar
• Beers MF, Morrisey EE. The three R's of lung health and disease: repair, remodeling, and regeneration. J Clin Invest 2011; 121(6):2065–2073.
   PubMed Web of Science ®Google Scholar
• Tumgor G, Celik U, Alabaz D, Cetiner S, Yaman A, Yildizdas D, et al. Aetiological agents, interleukin-6, interleukin-8 and CRP concentrations in children with community- and hospital-acquired pneumonia. Ann Trop Paediatr 2006; 26(4):285–291.
   PubMed Web of Science ®Google Scholar
• Wilkinson TMA, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167(8):1090–1095.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Zhu J, Bandi V, Atmar RL, Hattotuwa K, Guntupalli KK, et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168(8):968–975.
   PubMed Web of Science ®Google Scholar
• Bhowmik A, Seemungal TAR, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55(2):114–120.
   PubMed Web of Science ®Google Scholar
• Glynn P, Coakley R, Kilgallen I, Murphy N, O'Neill S. Circulating interleukin 6 and interleukin 10 in community acquired pneumonia. Thorax 1999; 54(1):51–55.
   PubMed Web of Science ®Google Scholar
• Bohnet S, Kötschau U, Braun J, Dalhoff K. Role of interleukin-8 in community-acquired pneumonia: relation to microbial load and pulmonary function. Infection 1997; 25(2):95–100.
   PubMed Web of Science ®Google Scholar
• Ferrer M, Torres A, Martínez R, Ramírez P, Polverino E, Montull B, et al. Inhaled corticosteroids and systemic inflammatory response in community-acquired pneumonia: a prospective clinical study. Respirology 2014; 19(6):929–935.
   PubMed Web of Science ®Google Scholar
• Crisafulli E, Guerrero M, Menéndez R, Huerta A, Martinez R, Gimeno A, et al. Inhaled corticosteroids do not influence the early inflammatory response and clinical presentation of hospitalized subjects with COPD exacerbation. Respir Care 2014; 59(10):1550–1559.
   PubMed Web of Science ®Google Scholar
• Churg A, Zhou S, Wright JL. Matrix metalloproteinases in COPD. Eur Respir J 2012; 39(1):197–209.
   PubMed Web of Science ®Google Scholar
• Rovina N, Koutsoukou A, Koulouris NG. Inflammation and immune response in COPD: where do we stand? Mediators Inflamm 2013; 2013:9.
   Google Scholar
• Lanchou J, Corbel M, Tanguy M, Germain N, Boichot E, Theret N, et al. Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients. Crit Care Med 2003; 31(2):536–542.
   Google Scholar
• Suga M, Iyonaga K, Okamoto T, Gushima Y, Miyakawa H, Akaike T, et al. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2000; 162(5):1949–1956.
   PubMed Web of Science ®Google Scholar
• Yang S-F, Chu S-C, Chiang IC, Kuo W-F, Chiou H-L, Chou F-P, et al. Excessive matrix metalloproteinase-9 in the plasma of community-acquired pneumonia. Clin Chim Acta 2005; 352(1–2):209–215.
   PubMed Web of Science ®Google Scholar
• Puljiz I, Markotić A, Krajinović LC, Gužvinec M, Polašek O, Kuzman I. Mycoplasma pneumoniae in adult community-acquired pneumonia increases matrix metalloproteinase-9 serum level and induces its gene expression in peripheral blood mononuclear cells. Med Sci Monit 2012; 18(8):CR500–CR5.
   Google Scholar
• Omachi T, Eisner M, Rames A, Markovtsova L, Blanc P. Matrix metalloproteinase-9 predicts pulmonary status declines in alpha1-antitrypsin deficiency. Respir Res 2011; 12(1):35.
   PubMed Web of Science ®Google Scholar
• Vernooy JHJ, Lindeman JHN, Jacobs JA, Hanemaaijer R, Wouters EFM. INcreased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with copd*. Chest 2004; 126(6):1802–1810.
   PubMed Web of Science ®Google Scholar
• Schaaf B, Liebau C, Kurowski V, Droemann D, Dalhoff K. Hospital acquired pneumonia with high-risk bacteria is associated with increased pulmonary matrix metalloproteinase activity. BMC Pulm Med 2008; 8(1):12.
   Google Scholar
• Hartog CM, Wermelt JA, Sommerfeld CO, Eichler W, Dalhoff K, Braun J. Pulmonary matrix metalloproteinase excess in hospital-acquired pneumonia. Am J Respir Crit Care Med 2003; 167(4):593–598.
   PubMed Web of Science ®Google Scholar
• Chiang T-Y, Yu Y-L, Lin C-W, Tsao S-M, Yang S-F, Yeh C-B. The circulating level of MMP-9 and its ratio to TIMP-1 as a predictor of severity in patients with community-acquired pneumonia. Clin Chim Acta 2013; 424:261–266.
   PubMed Web of Science ®Google Scholar
• de la Torre MC, Bolibar I, Vendrell M, de Gracia J, Vendrell E, Rodrigo MJ, et al. Serum immunoglobulins in the infected and convalescent phases in community-acquired pneumonia. Respir Med 2013; 107(12):2038–2045.
   PubMed Web of Science ®Google Scholar
• O'Keeffe S, Gzel A, Drury R, Cullina M, Greally J, Finnegan P. Immunoglobulin G subclasses and spirometry in patients with chronic obstructive pulmonary disease. Eur Respir J 1991; 4(8):932–936.
   PubMed Web of Science ®Google Scholar
• Heidari B. The importance of C-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease. Caspian J Intern Med 2012; 3(2):428–435.
   PubMedGoogle Scholar
• Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjærg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175(3):250–255.
   PubMed Web of Science ®Google Scholar
• Broekhuizen R, Wouters EFM, Creutzberg EC, Schols AMWJ. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61(1):17–22.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Zaheer M, Ahmad Z, Akhtar J. The relationship between C-reactive protein and prognostic factors in chronic obstructive pulmonary disease. Multidiscip Respir Med 2013; 8(1):63.
   PubMed Web of Science ®Google Scholar
• Youssef HA, Nasseh S, Hafiz HA, Gawesh A. Evaluation of diagnostic and prognostic value of high sensitivity C reactive protein (Hs-CRP) in community acquired pneumonia. Egypt J Chest Dis Tuberc 2013; 62(2):301–304.
   Google Scholar
• Shukla SD, Sohal SS, O'Toole RF, Eapen MS, Walters EH. Platelet activating factor receptor: gateway for bacterial chronic airway infection in chronic obstructive pulmonary disease and potential therapeutic target. Expert Rev Respir Med 2015; 9(4):473–485.
   PubMed Web of Science ®Google Scholar
• Shukla SD, Shoal SS, Mahmood MQ, Reid D, Konard M, Walters EH.Airway epithelial platelet-activating factor receptor expression is markedly upregulated in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014; 9:853–861.
   Google Scholar
• Shukla SD FR, Gell DA, Latham RD, Sohal SS, Walters EH, O.Toole RF. An antagonist of the Platelet-Activating Factor receptor inhibits adherence of both non-typeable Haemophilus influenzae and Streptococcus pneumoniae to cultured human bronchial epithelial cells exposed to cigarette smoke. Int J Chron Obstruct Pulmon Dis 2016; [In Press].
   Google Scholar
• Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359(22):2355–2365.
   PubMed Web of Science ®Google Scholar
• Cabello H, Torres A, Celis R, El-Ebiary M, Puig de la Bellacasa J, Xaubet A, et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J 1997; 10(5):1137–1144.
   PubMed Web of Science ®Google Scholar
• Beasley V, Joshi PV, Singanayagam A, Molyneaux PL, Johnston SL, Mallia P. Lung microbiology and exacerbations in COPD. Int J Chron Obstruct Pulmon Dis 2012; 7:555–569.
   PubMed Web of Science ®Google Scholar
• Rijneveld AW, Weijer S, Florquin S, Speelman P, Shimizu T, Ishii S, et al. Improved host defense against pneumococcal pneumonia in platelet-activating factor receptor-deficient mice. J Infect Dis 2004; 189(4):711–716.
   PubMed Web of Science ®Google Scholar
• van der Sluijs KF, van Elden LJ, Nijhuis M, Schuurman R, Florquin S, Shimizu T, et al. Involvement of the platelet-activating factor receptor in host defense against Streptococcus pneumoniae during postinfluenza pneumonia. Am J Physiol Lung Cell Mol Physiol 2006; 290(1):L194–L199.
   PubMed Web of Science ®Google Scholar
• Seki M, Kosai K, Hara A, Imamura Y, Nakamura S, Kurihara S, et al. Expression and DNA microarray analysis of a platelet activating factor-related molecule in severe pneumonia in mice due to influenza virus and bacterial co-infection. Jpn J Infect Dis 2009; 62(1):6–10.
   PubMed Web of Science ®Google Scholar
• Shivshankar P, Boyd AR, Le Saux CJ, Yeh IT, Orihuela CJ. Cellular senescence increases expression of bacterial ligands in the lungs and is positively correlated with increased susceptibility to pneumococcal pneumonia. Aging cell 2011; 10(5):798–806.
   PubMed Web of Science ®Google Scholar
• Gutierrez P, Closa D, Piñer R, Bulbena O, Menéndez R, Torres A. Macrophage activation in exacerbated COPD with and without community-acquired pneumonia. Eur Respir J 2010; 36(2):285–291.
   PubMed Web of Science ®Google Scholar
• Jeffery PK. Comparison of the structural and inflammatory features of COPD and asthma giles F. Filley lecture. Chest 2000; 117(5, Supplement 1):251S–60S.
   Google Scholar
• Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157(3):822–826.
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Camargo CA. Prevalence of blood eosinophilia in hospitalized patients with acute exacerbation of COPD. Respirology 2016; 21(4):761–764.
   PubMed Web of Science ®Google Scholar
• Jones MR, Simms BT, Lupa MM, Kogan MS, Mizgerd JP. Lung NF-κB activation and neutrophil recruitment require IL-1 and TNF receptor signaling during pneumococcal pneumonia. J Immunol 2005; 175(11):7530–7535.
   PubMed Web of Science ®Google Scholar
• Calbo E, Alsina M, Rodríguez-Carballeira M, Lite J, Garau J. Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a β-lactam versus a fluoroquinolone. Antimicrob Agents Chemother 2008; 52(7):2395–2402.
   PubMed Web of Science ®Google Scholar
• Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153(2):530–534.
   PubMed Web of Science ®Google Scholar
• de Boer WI, Sont JK, van Schadewijk A, Stolk J, van Krieken JH, Hiemstra PS. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol 2000; 190(5):619–626.
   PubMed Web of Science ®Google Scholar
• Çalıkoglu M, Şahin G, Unlu A, Ozturk C, Tamer L, Ercan B, et al. Leptin and TNF-Alpha levels in patients with chronic obstructive pulmonary disease and their relationship to nutritional parameters. Respiration 2004; 71(1):45–50.
   PubMed Web of Science ®Google Scholar
• Hong J-S, Greenlee KJ, Pitchumani R, Lee S-H, Song L, Shan M, et al. Dual protective mechanisms of matrix metalloproteinases 2 and 9 in immune defense against streptococcus pneumoniae. J Immunol 2011; 186(11):6427–6436.
   PubMed Web of Science ®Google Scholar
• Ilumets H, Rytilä PH, Sovijärvi AR, Tervahartiala T, Myllärniemi M, Sorsa TA, et al. Transient elevation of neutrophil proteinases in induced sputum during COPD exacerbation. Scand J Clin Lab Invest 2008; 68(7):618–623.
   PubMed Web of Science ®Google Scholar